Companies CG Oncology, Inc.
CG Oncology (CGON): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me CG Oncology, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers80th pct.Of 16 peer CEOs
CEO pay, last three years
- $3,933,996FY2023
- $11,172,793FY2024
- $11,928,401FY2025
CEO total pay was $11,928,401 in fiscal 2025, up from $11,172,793 in fiscal 2024.
FY2025: salary $690,000 · bonus $0 · stock awards $3,451,884 · option awards $7,350,515
Executives and directors
Arthur Kuan · CEOJim DeTore · CFOAmbaw Bellete · PresidentJoshua Patterson · General CounselRobert Lapetina · ExecutiveVijay Kasturi · Chief Medical OfficerCorleen Roche · CFOBrian Liu, M.D · Independent DirectorChristina Rossi · Independent DirectorJames J. Mulé, Ph.D · Independent DirectorLeonard Post, Ph.D · Lead Independent DirectorSimone Song · Former director (through FY2025)Susan Graf · Independent DirectorVictor Tong, Jr · Independent Director
Frequently asked questions
Who was the highest-paid executive at CG Oncology, Inc. in fiscal 2025?
As disclosed, Arthur Kuan (Chairman and Chief Executive Officer) was the highest-paid executive at CG Oncology, Inc. in fiscal 2025, with total compensation of $11,928,401.
How does CG Oncology, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Arthur Kuan's total compensation ranked at the 80th percentile of CG Oncology, Inc.'s disclosed peer group.
What is CG Oncology, Inc.'s CEO-to-median employee pay ratio?
As disclosed, CG Oncology, Inc.'s CEO-to-median employee pay ratio was 39.6:1.
How did shareholders vote on CG Oncology, Inc.'s executive compensation?
As disclosed, 97.63% of shareholders supported CG Oncology, Inc.'s executive compensation in the latest say-on-pay vote.
How much does CG Oncology, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, CG Oncology, Inc. reported total board compensation of $387,229 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Arthur Kuan | $690,000 | $0 | $3,451,884 | $7,350,515 | $414,000 | $0 | $22,002 | $11,928,401 |
| Chairman and Chief Executive Officer | ||||||||
| Ambaw Bellete | 537,941 | 0 | 0 | 3,967,601 | 268,971 | 0 | 40,879 | 4,815,391 |
| President and Chief Operating Officer | ||||||||
| Vijay Kasturi | 502,932 | 0 | 0 | 2,839,963 | 226,319 | 0 | 30,732 | 3,599,947 |
| Chief Medical Officer | ||||||||
| Joshua Patterson | 461,523 | 0 | 0 | 1,670,561 | 207,685 | 0 | 24,611 | 2,364,380 |
| General Counsel, Chief Compliance Officer, and Secretary | ||||||||
| Corleen Roche | 288,890 | 0 | 0 | 2,004,682 | 0 | 0 | 28,727 | 2,322,299 |
| Prior Chief Financial Officer | ||||||||
| Robert Lapetina | 310,224 | 2,250 | 0 | 300,702 | 0 | 0 | 32,121 | 645,297 |
| Prior Interim Principal Financial and Accounting Officer | ||||||||
| Jim DeTore | 96,000 | 0 | 0 | 0 | 0 | 0 | 0 | 96,000 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Arthur Kuan | $11,928,401 | $11,172,793 | $3,933,996 | ↑ +755,608 |
| Ambaw Bellete | 4,815,391 | 5,241,391 | 3,028,675 | ↓ −426,000 |
| Vijay Kasturi | 3,599,947 | — | — | — |
| Joshua Patterson | 2,364,380 | — | — | — |
| Corleen Roche | 2,322,299 | 9,845,800 | — | ↓ −7,523,501 |
| Robert Lapetina | 645,297 | — | — | — |
| Jim DeTore | 96,000 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company aims to provide executive officers with a reasonable level of security through base salary and benefits, while rewarding them through cash and equity-based incentive compensation to achieve business objectives and create stockholder value. The program is designed to attract, retain, and reward qualified Named Executive Officers by aligning their interests with those of stockholders through a competitive, well-balanced structure that rewards meaningful performance.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Arthur Kuan | PSU | 2025-09-25 | 18,925 | 94,624 | — | 94,624 | $3,451,884 |
| Joshua Patterson | OPTION | 2025-04-15 | — | — | 119,922 | — | 1,670,561 |
| Robert Lapetina | OPTION | 2025-04-15 | — | — | 21,586 | — | 300,702 |
| Vijay Kasturi | OPTION | 2025-04-15 | — | — | 203,868 | — | 2,839,963 |
| Ambaw Bellete | OPTION | 2025-04-15 | — | — | 284,816 | — | 3,967,601 |
| Arthur Kuan | OPTION | 2025-04-15 | — | — | 527,660 | — | 7,350,515 |
| Corleen Roche | OPTION | 2025-04-15 | — | — | 143,907 | — | 2,004,682 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Arthur Kuan | $0 | $3,451,884 | $7,350,515 | 32.0% |
| Joshua Patterson | 0 | 0 | 1,670,561 | 0.0% |
| Robert Lapetina | 0 | 0 | 300,702 | 0.0% |
| Vijay Kasturi | 0 | 0 | 2,839,963 | 0.0% |
| Ambaw Bellete | 0 | 0 | 3,967,601 | 0.0% |
| Corleen Roche | 0 | 0 | 2,004,682 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Ambaw Bellete | Option | 6,552 | 1.82 | — |
| Vijay Kasturi | Option | 18,336 | 12.59 | — |
| Ambaw Bellete | Option | 26,208 | 12.59 | — |
| Joshua Patterson | Option | 33,841 | 36.63 | — |
| Arthur Kuan | Option | 41,928 | 12.59 | — |
| Joshua Patterson | Option | 62,500 | 28.01 | — |
| Arthur Kuan | Option | 85,210 | 2.29 | — |
| Vijay Kasturi | Option | 93,926 | 36.63 | — |
| Arthur Kuan | PSU | 94,624 | — | 785,758 |
| Joshua Patterson | Option | 99,935 | 20.11 | — |
| Ambaw Bellete | Option | 124,313 | 36.63 | — |
| Vijay Kasturi | Option | 169,890 | 20.11 | — |
| Ambaw Bellete | Option | 171,114 | 3.72 | — |
| Vijay Kasturi | Option | 209,486 | 5.06 | — |
| Arthur Kuan | Option | 229,404 | 6.68 | — |
| Ambaw Bellete | Option | 237,347 | 20.11 | — |
| Arthur Kuan | Option | 281,776 | 36.63 | — |
| Arthur Kuan | Option | 439,717 | 20.11 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Christina RossiIndependent · Compensation · Partial-year service · Newly elected | $4,647 | $0 | $570,504 | $0 | $0 | $575,150 |
| Leonard Post, Ph.DIndependent · Lead Independent Director · Compensation (Chair) · Nominating/Governance · Partial-year service | 87,500 | 0 | 412,627 | 0 | 0 | 500,127 |
| Susan GrafIndependent · Audit (Chair) · Nominating/Governance | 70,000 | 0 | 412,627 | 0 | 0 | 482,627 |
| Simone SongIndependent · Departed during FY | 62,582 | 0 | 412,627 | 0 | 0 | 475,209 |
| Brian Liu, M.DIndependent · Audit · Compensation · Partial-year service | 62,500 | 0 | 412,627 | 0 | 0 | 475,127 |
| Victor Tong JrIndependent · Nominating/Governance (Chair) · Audit | 55,000 | 0 | 412,627 | 0 | 0 | 467,627 |
| James J. Mulé, Ph.DIndependent · Partial-year service | 45,000 | 0 | 412,627 | 0 | 0 | 457,627 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $400,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $387,229 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $387,229 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names CG Oncology as a peer
Companies that benchmark against CGON
3 companies name CGON as a compensation peer
- LIGAND PHARMACEUTICALS INCLGNDFY2025
- Perspective Therapeutics, Inc.CATXFY2025
Each company listed discloses CGON in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CGON in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ACLX Arcellx IDEAYAVERA VeraARVN ArvinasAGIO AgiosARWR ArrowheadIOVA IovanceAKRO AkeroIBRX ImmunityBioNMRA NeumoraDNLI DenaliIMVT ImmunovantSNDX SyndaxRCUS ArcusGERN GeronNTLA Intellia
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Arcellx | 2024 | Rami Elghandour | $653,288 | $9,342,069 | $10,850,151 | $0 | $21,402,668 |
| 2 | Immunovant | 2026 | Eric Venker | 636,618 | 0 | 19,010,639 | 0 | 20,158,767 |
| 3 | ImmunityBio | 2025 | Richard Adcock | 831,667 | 2,787,828 | 8,353,406 | 485,166 | 12,716,953 |
| 4 | CG Oncology, Inc. | 2025 | Arthur Kuan | 690,000 | 3,451,884 | 7,350,515 | 414,000 | 11,928,401 |
| 5 | Akero | 2024 | Andrew Cheng | 686,000 | 2,879,155 | 6,489,100 | 411,600 | 10,465,855 |
| 6 | Geron | 2025 | Harout Semerjian | 321,538 | 0 | 9,695,400 | 203,000 | 10,221,755 |
| 7 | Arcus | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 8 | Arrowhead | 2025 | Christopher Anzalone | 981,046 | 6,810,292 | 0 | 1,236,000 | 9,029,861 |
| 9 | Syndax | 2025 | Michael Metzger | 754,300 | 2,021,965 | 3,454,360 | 848,588 | 7,089,213 |
| 10 | Vera | 2025 | Marshall Fordyce | 660,000 | 2,356,285 | 3,415,725 | 554,400 | 6,986,410 |
| 11 | Arvinas | 2025 | John Houston | 706,236 | 2,685,840 | 2,671,051 | 457,000 | 6,534,127 |
| 12 | Agios | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
| 13 | Intellia | 2025 | John Leonard | 708,000 | 2,443,920 | 1,356,320 | 0 | 5,063,899 |
| 14 | Denali | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 15 | Neumora | 2025 | Paul Berns | 700,000 | 0 | 3,326,181 | 504,000 | 4,562,461 |
| 16 | Iovance | 2025 | Frederick Vogt | 800,000 | 759,375 | 0 | 312,000 | 1,888,175 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| CG Oncology, Inc. | 100% | Options 72 · PSU 28 | No | Pay Governance |
| Agios | 100% | Option 40 · PSU 40 · RSU 20 | No | Aon |
| Akero | 100% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Arcellx | 140% | not disclosed | No | Meridian Compensation Partners |
| Arcus | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Arrowhead | 125% | PRSU 70 · RSU 30 | not disclosed | Compensia |
| Arvinas | 108% | Options 50 · RSU 50 | not disclosed | Aon (Aon's Human Capital Solutions practice, a division of Aon plc) |
| Denali | 145% | not disclosed | not disclosed | Alpine Rewards |
| Geron | 90% | Options 75 · RSU 25 | not disclosed | Aon |
| ImmunityBio | not disclosed | Option 75 · RSU 25 | not disclosed | Mercer |
| Immunovant | 110% | not disclosed | No | Compensia |
| Intellia | 115% | Option 40 · RSU 40 · PSU 20 | Yes — TSR relative to the Nasdaq Biotechnology Index | Alpine |
| Iovance | 60% | not disclosed | No | Haigh & Company |
| Neumora | not disclosed | Options 100 | not disclosed | Alpine Rewards, LLC |
| Syndax | 150% | Options 34 · PSU 33 · RSU 33 | Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRs | Aon |
| Vera | not disclosed | RSU 50 · Options 50 | not disclosed | Alpine Rewards |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-04 | 65,894,959 | 1,603,011 | 123,356 | 97.63% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-04 | 97.63%a |
a. Approved under the standard stated in the filing — “An abstention does not count as a vote cast.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 39.6 : 1 |
|---|---|
| CEO total compensation | $11,928,401 |
| Median employee compensation | $301,336 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| James Mulay | Director | 2026-06-04 | A | 9,354 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-04 | — | 1,000 | — | — | 1 insider, 1 accrual row | ||
| Leonard E. Post | Director | 2026-06-04 | D | 1,000 | 55 | 54,500 | Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-06-04 | A | 1,000 | 1 | 600 | Common | Form 4 ↗ |
| Susan Graf | Director | 2026-06-04 | A | 9,354 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christina Rossi | Director | 2026-06-04 | A | 9,354 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Guan-Chyun Liu | Director | 2026-06-04 | A | 9,354 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-06-04 | A | 9,354 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Victor Tong Jr | Director | 2026-06-04 | A | 9,354 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-15 | — | 1,964 | — | — | 1 insider, 2 accrual rows | ||
| James Mulay | Director | 2026-06-15 | A | 1,310 | 13 | 16,493 | Common | Form 4 ↗ |
| James Mulay | Director | 2026-06-15 | D | 654 | 60 | 39,318 | Common | Form 4 ↗ |
| James Mulay | Director | 2026-06-15 | A | 654 | 4 | 2,433 | Common | Form 4 ↗ |
| James Mulay | Director | 2026-06-15 | D | 1,310 | 60 | 78,757 | Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-06-22 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-06-22 | D | 5,000 | 65 | 325,000 | Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-06-22 | A | 5,000 | 1 | 3,000 | Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-06-24 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-06-24 | D | 5,000 | 70 | 350,000 | Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-06-24 | A | 5,000 | 1 | 3,000 | Common | Form 4 ↗ |
| Brian Guan-Chyun Liu | Director | 2026-06-25 | A | 371,085 | 67 | 24,814,454 | Common, indirect | Form 4 ↗ |
| James Mulay | Director | 2026-07-10 | D | 24,165 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mulay | Director | 2026-07-10 | D | 24,165 | 75 | 1,816,241 | Common | Form 4 ↗ |
| James Mulay | Director | 2026-07-10 | A | 24,165 | 27 | 643,514 | Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-07-15 | A | 1,000 | 1 | 600 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-15 | — | 1,000 | — | — | 1 insider, 1 accrual row | ||
| Leonard E. Post | Director | 2026-07-15 | D | 1,000 | 71 | 71,170 | Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-08-14 | A | 1,000 | 1 | 600 | Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-08-14 | D | 1,000 | 75 | 74,540 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-08-14 | — | 1,000 | — | — | 1 insider, 1 accrual row | ||
| Leonard E. Post | Director | 2026-09-15 | A | 1,000 | 1 | 600 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-09-15 | — | 1,000 | — | — | 1 insider, 1 accrual row | ||
| Leonard E. Post | Director | 2026-09-15 | D | 1,000 | 73 | 72,980 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-10-15 | — | 1,000 | — | — | 1 insider, 1 accrual row | ||
| Leonard E. Post | Director | 2026-10-15 | D | 500 | 62 | 31,240 | Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-10-15 | D | 500 | 62 | 30,825 | Common | Form 4 ↗ |
| Isabel Kalofonos | Chief Commercial Officer | 2026-10-15 | A | 92,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-10-15 | A | 1,000 | 1 | 600 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 39 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| James Mulay | Director | 2026-06-04 | A | 9,354 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-06-04 | D | 1,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-06-04 | D | 1,000 | 55 | 54,500 | Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-06-04 | A | 1,000 | 1 | 600 | Common | Form 4 ↗ |
| Susan Graf | Director | 2026-06-04 | A | 9,354 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christina Rossi | Director | 2026-06-04 | A | 9,354 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Guan-Chyun Liu | Director | 2026-06-04 | A | 9,354 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-06-04 | A | 9,354 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Victor Tong Jr | Director | 2026-06-04 | A | 9,354 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mulay | Director | 2026-06-15 | D | 1,310 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mulay | Director | 2026-06-15 | D | 654 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mulay | Director | 2026-06-15 | A | 1,310 | 13 | 16,493 | Common | Form 4 ↗ |
| James Mulay | Director | 2026-06-15 | D | 654 | 60 | 39,318 | Common | Form 4 ↗ |
| James Mulay | Director | 2026-06-15 | A | 654 | 4 | 2,433 | Common | Form 4 ↗ |
| James Mulay | Director | 2026-06-15 | D | 1,310 | 60 | 78,757 | Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-06-22 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-06-22 | D | 5,000 | 65 | 325,000 | Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-06-22 | A | 5,000 | 1 | 3,000 | Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-06-24 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-06-24 | D | 5,000 | 70 | 350,000 | Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-06-24 | A | 5,000 | 1 | 3,000 | Common | Form 4 ↗ |
| Brian Guan-Chyun Liu | Director | 2026-06-25 | A | 371,085 | 67 | 24,814,454 | Common, indirect | Form 4 ↗ |
| James Mulay | Director | 2026-07-10 | D | 24,165 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Mulay | Director | 2026-07-10 | D | 24,165 | 75 | 1,816,241 | Common | Form 4 ↗ |
| James Mulay | Director | 2026-07-10 | A | 24,165 | 27 | 643,514 | Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-07-15 | A | 1,000 | 1 | 600 | Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-07-15 | D | 1,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-07-15 | D | 1,000 | 71 | 71,170 | Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-08-14 | A | 1,000 | 1 | 600 | Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-08-14 | D | 1,000 | 75 | 74,540 | Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-08-14 | D | 1,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-09-15 | A | 1,000 | 1 | 600 | Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-09-15 | D | 1,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-09-15 | D | 1,000 | 73 | 72,980 | Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-10-15 | D | 1,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-10-15 | D | 500 | 62 | 31,240 | Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-10-15 | D | 500 | 62 | 30,825 | Common | Form 4 ↗ |
| Isabel Kalofonos | Chief Commercial Officer | 2026-10-15 | A | 92,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leonard E. Post | Director | 2026-10-15 | A | 1,000 | 1 | 600 | Common | Form 4 ↗ |
Sources (81 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Arthur Kuan. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · page 37. As printed: 11,928,401. View filing ↗
- Section 01, Ambaw Bellete. DEF 14A, filed 2026-04-24. Section “Executive Compensation”. As printed: 4,815,391. View filing ↗
- Section 01, Vijay Kasturi. DEF 14A, filed 2026-04-24. Section “Executive Compensation”. As printed: 3,599,947. View filing ↗
- Section 01, Joshua Patterson. DEF 14A, filed 2026-04-24. Section “Executive Compensation”. As printed: 2,364,380. View filing ↗
- Section 01, Corleen Roche. DEF 14A, filed 2026-04-24. Section “Executive Compensation”. As printed: 2,322,299. View filing ↗
- Section 01, Robert Lapetina. DEF 14A, filed 2026-04-24. Section “Executive Compensation”. As printed: 645,297. View filing ↗
- Section 01, Jim DeTore. DEF 14A, filed 2026-04-24. Section “Executive Compensation”. As printed: 96,000. View filing ↗
- Section 03, Arthur Kuan PSU. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Joshua Patterson OPTION. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Robert Lapetina OPTION. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Vijay Kasturi OPTION. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Ambaw Bellete OPTION. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Arthur Kuan OPTION. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Corleen Roche OPTION. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-24. Section “CEO Pay Ratio”. As printed: 39.6 : 1. View filing ↗
- Section 08, Christina Rossi. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 575,150. View filing ↗
- Section 08, Leonard Post, Ph.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 500,127. View filing ↗
- Section 08, Susan Graf. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 482,627. View filing ↗
- Section 08, Simone Song. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 475,209. View filing ↗
- Section 08, Brian Liu, M.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 475,127. View filing ↗
- Section 08, Victor Tong Jr. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 467,627. View filing ↗
- Section 08, James J. Mulé, Ph.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 457,627. View filing ↗
- Section 02, James Mulay 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard E. Post 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard E. Post 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard E. Post 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susan Graf 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Rossi 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Guan-Chyun Liu 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard E. Post 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Victor Tong Jr 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Mulay 2026-06-15. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Mulay 2026-06-15. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Mulay 2026-06-15. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Mulay 2026-06-15. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Mulay 2026-06-15. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Mulay 2026-06-15. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard E. Post 2026-06-22. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard E. Post 2026-06-22. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard E. Post 2026-06-22. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard E. Post 2026-06-24. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard E. Post 2026-06-24. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard E. Post 2026-06-24. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Guan-Chyun Liu 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Mulay 2026-07-10. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Mulay 2026-07-10. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Mulay 2026-07-10. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard E. Post 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard E. Post 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard E. Post 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard E. Post 2026-08-14. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard E. Post 2026-08-14. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard E. Post 2026-08-14. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard E. Post 2026-09-15. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard E. Post 2026-09-15. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard E. Post 2026-09-15. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard E. Post 2026-10-15. Form 4, filed 2026-10-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard E. Post 2026-10-15. Form 4, filed 2026-10-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard E. Post 2026-10-15. Form 4, filed 2026-10-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Isabel Kalofonos 2026-10-15. Form 4, filed 2026-10-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard E. Post 2026-10-15. Form 4, filed 2026-10-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-08. Item 5.07 · say-on-pay result. As reported: 97.63% (votes for as printed: 65,894,959). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 387,229 + equity 0 + all other 0 = 387,229, summed across the director compensation table rows.
- Arcellx, Section 10b CEO total. DEF 14A, filed 2025-04-17. CEO total compensation as printed in Arcellx's own proxy. As printed: 21,402,668. View filing ↗
- Immunovant, Section 10b CEO total. DEF 14A, filed 2026-07-22. CEO total compensation as printed in Immunovant's own proxy. As printed: 20,158,767. View filing ↗
- ImmunityBio, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in ImmunityBio's own proxy. As printed: 12,716,953. View filing ↗
- CG Oncology, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in CG Oncology, Inc.'s own proxy. As printed: 11,928,401. View filing ↗
- Akero, Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Akero's own proxy. As printed: 10,465,855. View filing ↗
- Geron, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Geron's own proxy. As printed: 10,221,755. View filing ↗
- Arcus, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Arcus's own proxy. As printed: 9,656,813. View filing ↗
- Arrowhead, Section 10b CEO total. DEF 14A, filed 2026-01-27. CEO total compensation as printed in Arrowhead's own proxy. As printed: 9,029,861. View filing ↗
- Syndax, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Syndax's own proxy. As printed: 7,089,213. View filing ↗
- Vera, Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Vera's own proxy. As printed: 6,986,410. View filing ↗
- Arvinas, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Arvinas's own proxy. As printed: 6,534,127. View filing ↗
- Agios, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Agios's own proxy. As printed: 5,370,389. View filing ↗
- Intellia, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Intellia's own proxy. As printed: 5,063,899. View filing ↗
- Denali, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Denali's own proxy. As printed: 4,751,515. View filing ↗
- Neumora, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Neumora's own proxy. As printed: 4,562,461. View filing ↗
- Iovance, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Iovance's own proxy. As printed: 1,888,175. View filing ↗